Sosei Heptares Strikes Transformative Acquisition and License Deal with Idorsia – Get the Details at Today’s Investor and Press Conference!

Today, Sosei Group Corporation (“the Company”; TSE: 4565) is proud to announce a groundbreaking acquisition; “Sosei Heptares Acquires Idorsia’s Pharmaceuticals Business in Japan and APAC (ex-China), Accelerating its Transformation into a Fully Integrated Biopharmaceutical Company.”

To celebrate this major accomplishment, the company will be hosting an investor and press conference. Be part of this momentous occasion and join in as we move closer to becoming a fully integrated biopharmaceutical company.

We invite you to join us on Thursday, 20 July at 5pm JST (9am BST) for a virtual-in-person conference in Tokyo. Our event is for all existing and potential investors, sell-/buy-side analysts, and journalists.

During the event, you will have the opportunity to participate in a presentation with a Q&A session. Click here to pre-register for the webinar, and enjoy the convenience of simultaneous Japanese/English translation. We hope to see you there!

Check out our investor presentation slides now available in the investor section of our home page! If you missed the event, don’t worry – you can catch up with an archived streaming video on our website afterwards.

About Sosei Heptares

Sosei Heptares is a biopharmaceutical powerhouse committed to delivering life-changing drugs based on cutting-edge science to people around the world. Driven by a mission to become one of Japan’s premier biopharmaceutical flagships, we are dedicated to finding groundbreaking treatments for our patients.

Sosei Heptares is driving innovation with their leading development capability, leveraging opportunities to expand their already profitable and growing commercial operations in Japan into additional markets across the Asia-Pacific region. Harnessing this potential, they are paving the way for exciting new possibilities in the future.

Sosei Heptares is redefining the field of pharmaceuticals with its innovative StaR® technology and structure-based drug design platform, which it is utilizing to develop a multitude of new, cutting-edge medicines to help treat neurological, immunological, gastroenterological and inflammatory diseases. With its unprecedented scope, this promising foundation for the advancement of biomedical science is sure to make life-changing impacts on the lives of many.

At Arvinas, we’re leveraging our unparalleled discovery and development capabilities to create valuable partnerships with some of the leading names in biopharmaceuticals, including AbbVie, Genentech (Roche), GSK, Lilly, Neurocrine Biosciences, Novartis, Pfizer, Sanofi and Takeda. By forging these strategic partnerships, we are harnessing the potential of the latest advances in biopharmaceuticals to create a better future for the world.

Headquartered in Tokyo, Japan, Sosei Heptares is a cutting-edge biomedical innovation leader that has taken its groundbreaking research and development operations to the next level with expansive facilities in London and Cambridge, UK.

Sosei Heptares is the corporate brand and trademark of Sosei Group Corporation, a Tokyo Stock Exchange listed company (ticker: 4565). Consistently innovating through breakthroughs in research and development, Sosei Heptares is renowned for its world-leading StaR® technology. Their trademark logo is a mark of quality and reliability.

Leave a Comment